COLL - Collegium Pharmaceutical Non-GAAP EPS of $1.26 beats by $0.04 revenue of $135.5M misses by $2.91M

2023-08-03 16:14:51 ET

• Collegium Pharmaceutical press release ( NASDAQ: COLL ): Q2 Non-GAAP EPS of $1.26 beats by $0.04 .
• Revenue of $135.5M (+9.7% Y/Y) misses by $2.91M .
• Adjusted EBITDA for the 2023 Quarter was $85.8 million, compared to $71.2 million for the 2022 Quarter, representing a 21% increase year-over-year.
• The Company exited the 2023 Quarter with cash, cash equivalents and marketable securities of $325.5 million, up from $173.7 million as of December 31, 2022.

For further details see: